- Home
- PROK vs CLLS Comparison
PROK vs CLLS Comparison
Compare PROK & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | CLLS |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.6M | 394.4M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PROK | CLLS |
|---|---|---|
| Price | $1.56 | $2.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $7.40 | ★ $8.33 |
| AVG Volume (30 Days) | ★ 1.5M | 25.4K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $1.53 | $1.77 |
| 52 Week High | $4.05 | $5.48 |
Technical Indicators
Market Signals| Indicator | PROK | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 41.14 |
| Support Level | N/A | $2.70 |
| Resistance Level | $2.59 | $3.40 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 2.86 | 26.81 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.